Pre-market hot trades in US stocks: Freshworks pre-market down 8.68%; Atlassian pre-market down 8.44%

Freshworks pre-market down 8.68%; Atlassian pre-market down 8.44%; NextCure pre-market up 359.14%; Shuttle Pharmaceuticals pre-market up 45.27%; Vision Marine Tech pre-market up 31.91%

Pre-market Hot Trades in US Stocks

Freshworks, down 8.68% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Atlassian is down 8.44% in pre-market trading. Based on recent key news:

On July 11, a federal labor law judge ruled that Atlassian illegally fired an employee who questioned changes to company policy. This incident triggered a trust crisis in the company's management, leading to an 8.44% drop in stock price. The software industry faces regulatory risks.

Top Gainers in Pre-market US Stocks

NextCure is up 359.14% in pre-market trading. Based on recent key news:

On July 14, NextCure announced a merger with Avere Therapeutics, causing a significant rise in stock price. After the merger, the company will operate under the name Avere Therapeutics and plans to raise $320 million to develop the AVR-001 drug, pushing the stock price up by 93%. Source: GlobeNewswire
On July 14, Hansoh Pharmaceutical announced participation in Avere's directed issuance and granted it exclusive licensing, further boosting NextCure's stock price. Hansoh Pharmaceutical is expected to hold 30%-40% of the merged entity. Source: Hong Kong Stock Exchange announcement
On July 14, NextCure shareholders will receive rights to 90% of potential transaction profits, increasing investor confidence. This right applies to any licensing or transaction profits within two years after the merger. Source: GlobeNewswire. The biotechnology industry has seen frequent merger activities recently, with significant capital inflow.

Shuttle Pharmaceuticals is up 45.27% in pre-market trading. Based on recent news:

On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares on the open market at prices ranging from $3.11 to $3.38 per share. Following this news, market demand for the stock significantly increased, driving the stock price up sharply.
On July 13, HRT Financial reported a 10% stake in Shuttle Pharmaceuticals in Form 3 filings. The filings showed that as of July 9, HRT Financial directly held 60,540 shares of common stock. This disclosure of holdings enhanced investor confidence in the company's prospects, further pushing up the stock price. Market interest in the biopharmaceutical industry is increasing Vision Marine Tech pre-market rose by 31.91%. Based on recent key news:
On July 13, Vision Marine Technologies announced on the EDGAR system, disclosing recent financial and operational information. This announcement may have enhanced investor confidence in the company's future development, driving the stock price up.
On July 9, HRT Financial sold all of its 34,746 shares of common stock in Vision Marine Technologies at a price of $1.25 per share. Nevertheless, market demand for the stock remained strong, leading to a rise in the stock price in the following trading days.
Recently, Vision Marine Technologies has faced uncertainties such as supply chain disruptions, tariffs, and trade policies. However, the company's progress in battery supplier qualification and technology commercialization may have boosted market confidence, driving the stock price up. Supply chain disruptions and trade policies impact the market

Pre-market Hot Trades in US Stocks

Atlassian is down 8.44% in pre-market trading. Based on recent key news:

On July 11, a federal labor law judge ruled that Atlassian illegally fired an employee who questioned changes to company policy. This incident triggered a trust crisis in the company's management, leading to an 8.44% drop in stock price. The software industry faces regulatory risks.

Top Gainers in Pre-market US Stocks

NextCure is up 359.14% in pre-market trading. Based on recent key news:

On July 14, NextCure announced a merger with Avere Therapeutics, causing a significant rise in stock price. After the merger, the company will operate under the name Avere Therapeutics and plans to raise $320 million to develop the AVR-001 drug, pushing the stock price up by 93%. Source: GlobeNewswire
On July 14, Hansoh Pharmaceutical announced participation in Avere's directed issuance and granted it exclusive licensing, further boosting NextCure's stock price. Hansoh Pharmaceutical is expected to hold 30%-40% of the merged entity. Source: Hong Kong Stock Exchange announcement
On July 14, NextCure shareholders will receive rights to 90% of potential transaction profits, increasing investor confidence. This right applies to any licensing or transaction profits within two years after the merger. Source: GlobeNewswire. The biotechnology industry has seen frequent merger activities recently, with significant capital inflow.

Shuttle Pharmaceuticals is up 45.27% in pre-market trading. Based on recent news:

On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares on the open market at prices ranging from $3.11 to $3.38 per share. Following this news, market demand for the stock significantly increased, driving the stock price up sharply.
On July 13, HRT Financial reported a 10% stake in Shuttle Pharmaceuticals in Form 3 filings. The filings showed that as of July 9, HRT Financial directly held 60,540 shares of common stock. This disclosure of holdings enhanced investor confidence in the company's prospects, further pushing up the stock price. Market interest in the biopharmaceutical industry is increasing Vision Marine Tech pre-market rose by 31.91%. Based on recent key news:
On July 13, Vision Marine Technologies announced on the EDGAR system, disclosing recent financial and operational information. This announcement may have enhanced investor confidence in the company's future development, driving the stock price up.
On July 9, HRT Financial sold all of its 34,746 shares of common stock in Vision Marine Technologies at a price of $1.25 per share. Nevertheless, market demand for the stock remained strong, leading to a rise in the stock price in the following trading days.
Recently, Vision Marine Technologies has faced uncertainties such as supply chain disruptions, tariffs, and trade policies. However, the company's progress in battery supplier qualification and technology commercialization may have boosted market confidence, driving the stock price up. Supply chain disruptions and trade policies impact the market